141 related articles for article (PubMed ID: 8543404)
21. Induction therapy in a multiple myeloma mouse model using a combination of AS101 and melphalan, and the activity of AS101 in a tumor microenvironment model.
Hayun M; Saida H; Albeck M; Peled A; Haran-Ghera N; Sredni B
Exp Hematol; 2009 May; 37(5):593-603. PubMed ID: 19375650
[TBL] [Abstract][Full Text] [Related]
22. The effect of AS101 on the reconstitution of T-cell reactivity following irradiation or cyclophosphamide treatment.
Kalechman Y; Sotnik-Barkai I; Albeck M; Sredni B
Exp Hematol; 1992 Dec; 20(11):1302-8. PubMed ID: 1493859
[TBL] [Abstract][Full Text] [Related]
23. Protection against cytosine arabinoside-induced alopecia by minoxidil in a rat animal model.
Hussein AM
Int J Dermatol; 1995 Jul; 34(7):470-3. PubMed ID: 7591409
[TBL] [Abstract][Full Text] [Related]
24. Synergistic anti-tumoral effect of paclitaxel (Taxol)+AS101 in a murine model of B16 melanoma: association with ras-dependent signal-transduction pathways.
Kalechman Y; Longo DL; Catane R; Shani A; Albeck M; Sredni B
Int J Cancer; 2000 Apr; 86(2):281-8. PubMed ID: 10738258
[TBL] [Abstract][Full Text] [Related]
25. Antibabesial effect of the immunomodulator AS101 in mice: role of increased production of nitric oxide.
Rosenblatt-Bin H; Klein A; Sredni B
Parasite Immunol; 1996 Jun; 18(6):297-306. PubMed ID: 9229382
[TBL] [Abstract][Full Text] [Related]
26. Mechanism of radioprotection conferred by the immunomodulator AS101.
Kalechman Y; Gafter U; Barkai IS; Albeck M; Sredni B
Exp Hematol; 1993 Jan; 21(1):150-5. PubMed ID: 8417951
[TBL] [Abstract][Full Text] [Related]
27. The protective role of ammonium trichloro(dioxoethylene-O,O')tellurate in combination with several cytotoxic drugs acting by different mechanisms of action.
Kalechman Y; Shani A; Sotnik-Barkai I; Albeck M; Sredni B
Cancer Res; 1993 Dec; 53(24):5962-9. PubMed ID: 8261410
[TBL] [Abstract][Full Text] [Related]
28. In vivo synergistic effect of the immunomodulator AS101 and the PKC inducer bryostatin.
Kalechman Y; Albeck M; Sredni B
Cell Immunol; 1992 Aug; 143(1):143-53. PubMed ID: 1623562
[TBL] [Abstract][Full Text] [Related]
29. Protective effect of the immunomodulator AS101 against cyclophosphamide-induced testicular damage in mice.
Carmely A; Meirow D; Peretz A; Albeck M; Bartoov B; Sredni B
Hum Reprod; 2009 Jun; 24(6):1322-9. PubMed ID: 19240057
[TBL] [Abstract][Full Text] [Related]
30. Protection of bone marrow stromal cells from the toxic effects of cyclophosphamide in vivo and of ASTA-Z 7557 and etoposide in vitro by ammonium trichloro(dioxyethylene-O-O')tellurate (AS101).
Kalechman Y; Sotnik-Barkai I; Albeck M; Sredni B
Cancer Res; 1993 Apr; 53(8):1838-44. PubMed ID: 8467503
[TBL] [Abstract][Full Text] [Related]
31. The immunomodulator AS101 administered orally as a chemoprotective and radioprotective agent.
Sredni B; Albeck M; Kazimirsky G; Shalit F
Int J Immunopharmacol; 1992 May; 14(4):613-9. PubMed ID: 1521929
[TBL] [Abstract][Full Text] [Related]
32. Interleukin 1 protects against 1-beta-D-arabinofuranosylcytosine-induced alopecia in the newborn rat animal model.
Hussein AM
Cancer Res; 1991 Jun; 51(12):3329-30. PubMed ID: 2040008
[TBL] [Abstract][Full Text] [Related]
33. The effect of the novel tellurium compound AS101 on autoimmune diseases.
Halpert G; Sredni B
Autoimmun Rev; 2014 Dec; 13(12):1230-5. PubMed ID: 25153485
[TBL] [Abstract][Full Text] [Related]
34. Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.
Sculier JP; Lafitte JJ; Paesmans M; Thiriaux J; Alexopoulos CG; Baumöhl J; Schmerber J; Koumakis G; Florin MC; Zacharias C; Berghmans T; Mommen P; Ninane V; Klastersky J
Br J Cancer; 2000 Nov; 83(9):1128-35. PubMed ID: 11027424
[TBL] [Abstract][Full Text] [Related]
35. Immunologic effects of AS101 in the treatment of cancer patients.
Shani A; Tichler T; Catane R; Gurwith M; Rozenszajn LA; Gezin A; Levi E; Schlesinger M; Kalechman Y; Michlin H
Nat Immun Cell Growth Regul; 1990; 9(3):182-90. PubMed ID: 2370878
[TBL] [Abstract][Full Text] [Related]
36. Mesangial cells initiate compensatory renal tubular hypertrophy via IL-10-induced TGF-beta secretion: effect of the immunomodulator AS101 on this process.
Sinuani I; Averbukh Z; Gitelman I; Rapoport MJ; Sandbank J; Albeck M; Sredni B; Weissgarten J
Am J Physiol Renal Physiol; 2006 Aug; 291(2):F384-94. PubMed ID: 16571592
[TBL] [Abstract][Full Text] [Related]
37. Protection against chemotherapy-induced alopecia by cyclosporin A in the newborn rat animal model.
Hussein AM; Stuart A; Peters WP
Dermatology; 1995; 190(3):192-6. PubMed ID: 7599379
[TBL] [Abstract][Full Text] [Related]
38. Use and mechanism of action of AS101 in protecting bone marrow colony forming units-granulocyte-macrophage following purging with ASTA-Z 7557.
Kalechman Y; Barkai IS; Albeck M; Horwith G; Sehagl SN; Sredni B
Cancer Res; 1991 Oct; 51(20):5614-20. PubMed ID: 1913679
[TBL] [Abstract][Full Text] [Related]
39. Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101.
Frei GM; Kremer M; Hanschmann KM; Krause S; Albeck M; Sredni B; Schnierle BS
Br J Dermatol; 2008 Mar; 158(3):578-86. PubMed ID: 18241275
[TBL] [Abstract][Full Text] [Related]
40. The organotellurium compound ammonium trichloro(dioxoethylene-0,0') tellurate enhances neuronal survival and improves functional outcome in an ischemic stroke model in mice.
Okun E; Arumugam TV; Tang SC; Gleichmann M; Albeck M; Sredni B; Mattson MP
J Neurochem; 2007 Aug; 102(4):1232-41. PubMed ID: 17542809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
